Hadcock JR - Search Results

1

Downregulation of GPR83 in the hypothalamic preoptic area reduces core body temperature and elevates circulating levels of adiponectin.

Dubins JS, Sanchez-Alavez M, Zhukov V, Sanchez-Gonzalez A, Moroncini G, Carvajal-Gonzalez S, Hadcock JR, Bartfai T, Conti B. Dubins JS, et al. Among authors: hadcock jr. Metabolism. 2012 Oct;61(10):1486-93. doi: 10.1016/j.metabol.2012.03.015. Epub 2012 May 4. Metabolism. 2012. PMID: 22560055 Free PMC article.

2

AdipoR1 and 2 are expressed on warm sensitive neurons of the hypothalamic preoptic area and contribute to central hyperthermic effects of adiponectin.

Klein I, Sanchez-Alavez M, Tabarean I, Schaefer J, Holmberg KH, Klaus J, Xia F, Marcondes MC, Dubins JS, Morrison B, Zhukov V, Sanchez-Gonzalez A, Mitsukawa K, Hadcock JR, Bartfai T, Conti B. Klein I, et al. Among authors: hadcock jr. Brain Res. 2011 Nov 14;1423:1-9. doi: 10.1016/j.brainres.2011.09.019. Epub 2011 Sep 17. Brain Res. 2011. PMID: 22000082 Free PMC article.

3

Insulin causes hyperthermia by direct inhibition of warm-sensitive neurons.

Sanchez-Alavez M, Tabarean IV, Osborn O, Mitsukawa K, Schaefer J, Dubins J, Holmberg KH, Klein I, Klaus J, Gomez LF, Kolb H, Secrest J, Jochems J, Myashiro K, Buckley P, Hadcock JR, Eberwine J, Conti B, Bartfai T. Sanchez-Alavez M, et al. Among authors: hadcock jr. Diabetes. 2010 Jan;59(1):43-50. doi: 10.2337/db09-1128. Epub 2009 Oct 21. Diabetes. 2010. PMID: 19846801 Free PMC article.

4

Ccl22/MDC, is a prostaglandin dependent pyrogen, acting in the anterior hypothalamus to induce hyperthermia via activation of brown adipose tissue.

Osborn O, Sanchez-Alavez M, Dubins JS, Gonzalez AS, Morrison B, Hadcock JR, Bartfai T. Osborn O, et al. Among authors: hadcock jr. Cytokine. 2011 Mar;53(3):311-9. doi: 10.1016/j.cyto.2010.11.017. Epub 2010 Dec 21. Cytokine. 2011. PMID: 21177120 Free PMC article.

5

G protein-coupled receptor 21 deletion improves insulin sensitivity in diet-induced obese mice.

Osborn O, Oh DY, McNelis J, Sanchez-Alavez M, Talukdar S, Lu M, Li P, Thiede L, Morinaga H, Kim JJ, Heinrichsdorff J, Nalbandian S, Ofrecio JM, Scadeng M, Schenk S, Hadcock J, Bartfai T, Olefsky JM. Osborn O, et al. J Clin Invest. 2012 Jul;122(7):2444-53. doi: 10.1172/JCI61953. Epub 2012 Jun 1. J Clin Invest. 2012. PMID: 22653059 Free PMC article.

6

Postnatal PPARdelta activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice.

Bernardo BL, Wachtmann TS, Cosgrove PG, Kuhn M, Opsahl AC, Judkins KM, Freeman TB, Hadcock JR, LeBrasseur NK. Bernardo BL, et al. Among authors: hadcock jr. PLoS One. 2010 Jun 25;5(6):e11307. doi: 10.1371/journal.pone.0011307. PLoS One. 2010. PMID: 20593012 Free PMC article.

7

Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies.

Selimkhanov J, Thompson WC, Patterson TA, Hadcock JR, Scott DO, Maurer TS, Musante CJ. Selimkhanov J, et al. Among authors: hadcock jr. PLoS One. 2016 May 26;11(5):e0155674. doi: 10.1371/journal.pone.0155674. eCollection 2016. PLoS One. 2016. PMID: 27227543 Free PMC article.

8

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.

Hadcock JR, Griffith DA, Iredale PA, Carpino PA, Dow RL, Black SC, O'Connor R, Gautreau D, Lizano JS, Ward K, Hargrove DM, Kelly-Sullivan D, Scott DO. Hadcock JR, et al. Biochem Biophys Res Commun. 2010 Apr 2;394(2):366-71. doi: 10.1016/j.bbrc.2010.03.015. Epub 2010 Mar 6. Biochem Biophys Res Commun. 2010. PMID: 20211605

9

Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.

Hadcock JR, Carpino PA, Iredale PA, Dow RL, Gautreau D, Thiede L, Kelly-Sullivan D, Lizano JS, Liu X, Van Deusen J, Ward KM, O'Connor RE, Black SC, Griffith DA, Scott DO. Hadcock JR, et al. BMC Pharmacol. 2010 Aug 16;10:9. doi: 10.1186/1471-2210-10-9. BMC Pharmacol. 2010. PMID: 20712891 Free PMC article.

10

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.

Griffith DA, Hadcock JR, Black SC, Iredale PA, Carpino PA, DaSilva-Jardine P, Day R, DiBrino J, Dow RL, Landis MS, O'Connor RE, Scott DO. Griffith DA, et al. Among authors: hadcock jr. J Med Chem. 2009 Jan 22;52(2):234-7. doi: 10.1021/jm8012932. J Med Chem. 2009. PMID: 19102698

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page